Celltrion Earnings Jump: Profit Growth Signals Upside Celltrion is rated Buy as revenue rose 45% and net profit jumped 505% YoY, signaling strong operating leverage, with targets implying upside. Key risks: profit normalization and biosimilar competition. 2026년 10월 09일 English
Celltrion Earnings Soar: Profit Surge Signals Upside Celltrion shows strong revenue growth and rapidly expanding earnings and margins, with analysts broadly rating it Buy; stock trades below average targets, though repeatability of profit surge is the key risk. 2026년 09월 09일 English
Celltrion Earnings Jump Shows Stronger Growth Potential Celltrion is rated Buy as analysts expect upside; latest quarter shows revenue +36% YoY but operating profit +115% and net profit +219%, driven by U.S. biosimilar expansion. 2026년 07월 23일 English
Celltrion Earnings Soar – Strong Growth and Margin Upside Celltrion shows strong revenue growth and accelerating profits, driven by higher margin product mix and improving costs, supporting a bullish Buy consensus. 2026년 07월 03일 English
Celltrion Earnings Accelerate: Margin Gains Boost Outlook Celltrion BUY: operating profit and net income surged YoY, driven by strong margin expansion; stock near lowest target supports upside, but sustainability and valuation risk remain. 2026년 05월 08일 English
Celltrion Stock Momentum Shifts: Margin And Earnings Surge Celltrion is rated Buy as margins expand rapidly, operating profit accelerates, and three ADCs have moved to patient dosing with US fast track, supporting upside. 2026년 04월 28일 English
